Definium Therapeutics, Inc.
DFTX- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001813814
In the last 90 days, Definium Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 362 institutions reported holding it in 13F filings for Q2 2026, worth $5.35B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in Definium Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 104
- +12 vs. Q3 2023
- Shares held
- 4.88M
- +1.01M (+26.0%) vs. Q3 2023
- Total value
- $17.9M
- +$5.74M (+47.3%) vs. Q3 2023
- New holders
- 21
- 22 more added
- Sold out
- 9
- 20 more reduced
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DFTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 362 | $5.35B |
| Q1 2026 | 248 | $1.47B |
| Q4 2025 | 209 | $908.7M |
| Q3 2025 | 196 | $468.6M |
| Q2 2025 | 183 | $271.0M |
| Q1 2025 | 191 | $240.5M |
| Q4 2024 | 174 | $288.9M |
| Q3 2024 | 158 | $281.6M |
| Q2 2024 | 152 | $299.3M |
| Q1 2024 | 135 | $327.2M |
| Q4 2023 | 104 | $17.9M |
| Q3 2023 | 93 | $12.1M |
| Q2 2023 | 84 | $13.9M |
| Q1 2023 | 89 | $12.6M |
| Q4 2022 | 104 | $11.1M |
| Q3 2022 | 101 | $20.5M |
| Q2 2022 | 156 | $15.1M |
| Q1 2022 | 159 | $53.6M |
| Q4 2021 | 176 | $72.0M |
| Q3 2021 | 175 | $104.8M |
| Q2 2021 | 156 | $131.0M |
| Q1 2021 | 8 | $932.0K |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Definium Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 377,915 | $1.38M | 0.00% | +6,602+1.8% | Added |
| BlackRock Inc. | 550,617 | $2.02M | 0.00% | +1,536+0.3% | Added |
| Vanguard Group Inc | 567,885 | $2.08M | 0.00% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 600,000 | $2.20M | 0.60% | +600,000 | New |
| Virtu Financial LLC | 0 | $0 | 0.00% | −28,494−100.0% | Sold out |
| GTS Securities LLC | 0 | $0 | 0.00% | −19,854−100.0% | Sold out |
| North Star Investment Management Corp. | 0 | $0 | 0.00% | −14,860−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −11,545−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −218−100.0% | Sold out |
| Impact Partnership Wealth, LLC | 0 | $0 | 0.00% | −48−100.0% | Sold out |
| FinTrust Capital Advisors, LLC | 0 | $0 | 0.00% | −33−100.0% | Sold out |
| Gradient Investments LLC | 0 | $0 | 0.00% | −18−100.0% | Sold out |
| VisionPoint Advisory Group, LLC | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| Column Capital Advisors, LLC | – | – | – | – | Not filed |